Fowler A, Hebron M, Missner A, Wang R, Gao X, Kurd Misto B, et al. Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. Drugs R D. 2019;19:149-166 pubmed publisher

Mollenhauer B, Bowman F, Drake D, Duong J, Blennow K, El Agnaf O, et al. Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. J Neurochem. 2019;149:126-138 pubmed publisher

Zunke F, Moise A, Belur N, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron. 2018;97:92-107.e10 pubmed publisher

Goldman J, Andrews H, Amara A, Naito A, Alcalay R, Shaw L, et al. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. 2018;33:282-288 pubmed publisher

Eidson L, Kannarkat G, Barnum C, Chang J, Chung J, Caspell Garcia C, et al. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease. J Neuroinflammation. 2017;14:164 pubmed publisher

Mollenhauer B, Batrla R, El Agnaf O, Galasko D, Lashuel H, Merchant K, et al. A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations. Mov Disord. 2017;32:1117-1130 pubmed publisher

Oeckl P, Metzger F, Nagl M, von Arnim C, Halbgebauer S, Steinacker P, et al. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. Mol Cell Proteomics. 2016;15:3126-3138 pubmed

Mollenhauer B, Zimmermann J, Sixel Döring F, Focke N, Wicke T, Ebentheuer J, et al. Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology. 2016;87:168-77 pubmed publisher

Kang J, Mollenhauer B, Coffey C, Toledo J, Weintraub D, Galasko D, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol. 2016;131:935-49 pubmed publisher

Kruse N, Persson S, Alcolea D, Bahl J, Baldeiras I, Capello E, et al. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiol Aging. 2015;36:2587-96 pubmed publisher